Silo Pharma, Inc (OTCQB:SILO) CEO, Eric Weisblum presents at Proactive's One2One virtual investor forum.
Silo Pharma is bridging the gap between traditional pharmaceuticals and the emerging psychedelics space. The developmental-stage biopharmaceutical company’s mission is to identify assets to license and fund the research which it believes could transform both the well-being of patients and the healthcare system at large.
Price: 0.285 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Silo Pharma Inc named herein, including the promotion by the Company of Silo Pharma Inc in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE
We are delighted to invite you to attend the next Proactive ONE2ONE Investor Forum which is taking place on Tuesday February 23rd from 1pm EST via our online interactive webinar conference Proactive continues to bring you the best investment opportunities safely to the comfort of your own...
Basic Materials
Prev article
